- Home
- SAVA vs SRTS Comparison
SAVA vs SRTS Comparison
Compare SAVA & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SRTS
- Stock Information
- Founded
- SAVA 1998
- SRTS 2010
- Country
- SAVA United States
- SRTS United States
- Employees
- SAVA N/A
- SRTS N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- SAVA Health Care
- SRTS Health Care
- Exchange
- SAVA Nasdaq
- SRTS Nasdaq
- Market Cap
- SAVA 135.9M
- SRTS 110.3M
- IPO Year
- SAVA N/A
- SRTS 2016
- Fundamental
- Price
- SAVA $2.75
- SRTS $6.56
- Analyst Decision
- SAVA Buy
- SRTS Strong Buy
- Analyst Count
- SAVA 3
- SRTS 2
- Target Price
- SAVA $111.50
- SRTS $12.50
- AVG Volume (30 Days)
- SAVA 3.4M
- SRTS 240.1K
- Earning Date
- SAVA 02-26-2025
- SRTS 02-06-2025
- Dividend Yield
- SAVA N/A
- SRTS N/A
- EPS Growth
- SAVA N/A
- SRTS N/A
- EPS
- SAVA N/A
- SRTS 0.57
- Revenue
- SAVA N/A
- SRTS $41,308,000.00
- Revenue This Year
- SAVA N/A
- SRTS $65.04
- Revenue Next Year
- SAVA N/A
- SRTS $24.87
- P/E Ratio
- SAVA N/A
- SRTS $11.53
- Revenue Growth
- SAVA N/A
- SRTS 65.62
- 52 Week Low
- SAVA $2.23
- SRTS $2.61
- 52 Week High
- SAVA $42.20
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- SAVA 30.54
- SRTS 37.12
- Support Level
- SAVA $2.65
- SRTS $6.38
- Resistance Level
- SAVA $2.83
- SRTS $6.93
- Average True Range (ATR)
- SAVA 0.24
- SRTS 0.40
- MACD
- SAVA 0.59
- SRTS -0.03
- Stochastic Oscillator
- SAVA 52.75
- SRTS 13.64
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.